Asymptomatic changes in cardiac function can occur in ductal carcinoma-in-situ patients following treatment with HER-2/neu-pulsed dendritic cell vaccines

American Journal of Surgery

Volumn 198, Issue 4, 2009, Pages 488-494

  Bahl, Susan ^a   Roses, Robert E ^a   Sharma, Anupama ^a   Koldovsky, Ursula ^a   Xu, Shuwen ^a   Weinstein, Susan ^a   Nisenbaum, Harvey ^a   Fox, Kevin ^a   Pasha, Theresa ^a   Zhang, Paul ^a   Araujo, Louis ^a   Carver, Joseph ^a   Czerniecki, Brian J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Cardiac toxicity; DCIS; Dendritic cells; HER 2; Trastuzumab; Vaccinations

Indexed keywords

DENDRITIC CELL VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; TRASTUZUMAB;

ADULT; AGED; ANTIBODY DETECTION; ARTICLE; CANCER ADJUVANT THERAPY; CARDIOTOXICITY; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG TARGETING; ECHOCARDIOGRAPHY; FEMALE; HEART DISEASE; HEART EJECTION FRACTION; HEART FUNCTION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; PATIENT MONITORING; PRIORITY JOURNAL; SIDE EFFECT; VACCINATION;

ADULT; AGED; BREAST NEOPLASMS; CANCER VACCINES; CARCINOMA, INTRADUCTAL, NONINFILTRATING; DENDRITIC CELLS; FEMALE; GENES, ERBB-2; HUMANS; MIDDLE AGED; STROKE VOLUME; VENTRICULAR DYSFUNCTION;

EID: 70349562255     PISSN: 00029610     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjsurg.2009.06.014     Document Type: Article

References (29)

1. Schechter A.L., Hung M.C., Vaidyanathan L., et al. The neu gene: an erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor. Science 229 (1985) 976-978
2. Schechter A.L., Stern D.F., Vaidyanathan L., et al. The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature 312 (1984) 513-516
3. Baxevanis C.N., Sotiropoulou P.A., Sotiriadou N.N., et al. Immunobiology of HER-2/neu oncoprotein and its potential application in cancer immunotherapy. Cancer Immunol Immunother 53 (2004) 166-175
4. Cobleigh M.A., Vogel C.L., Tripathy D., et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17 (1999) 2639-2648
5. Esteva F.J., Valero V., Booser D., et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 20 (2002) 1800-1808
6. Bartsch R., Wenzel C., Hussian D., et al. Analysis of trastuzumab and chemotherapy in advanced breast cancer after the failure of at least one earlier combination: an observational study. BMC Cancer 6 (2006) 63
7. Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344 (2001) 783-792
8. Robert N., Leyland-Jones B., Asmar L., et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 24 (2006) 2786-2792
9. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353 (2005) 1659-1672
10. Cuello M., Ettenberg S.A., Clark A.S., et al. Downregulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2. Cancer Res 61 (2001) 4892-4900
11. Nahta R., and Esteva F.J. Herceptin: mechanisms of action and resistance. Cancer Lett 232 (2006) 123-138
12. Cooley S., Burns L.J., Repka T., et al. Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu. Exp Hematol 27 (1999) 1533-1541
13. Clynes R.A., Towers T.L., Presta L.G., et al. Receptors modulate in vivo cytoxicity against tumor targets. Nat Med 6 (2000) 443-446
14. Musolino A., Naldi N., Bortesi B., et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 26 (2008) 1789-1796
15. Vogel C.L., Cobleigh M.A., Tripathy D., et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20 (2002) 719-726
16. Guarneri V., Lenihan D.J., Valero V., et al. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. J Clin Oncol 24 (2006) 4107-4115
17. Lee K.F., Simon H., Chen H., et al. Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature 378 (1995) 394-398
18. Crone S.A., Zhao Y.Y., Fan L., et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 8 (2002) 459-465
19. Disis M.L., Gooley T.A., Rinn K., et al. Generation of T-cell immunity to the HER-2/neu Protein After active immunization with HER-2/neu peptide-based vaccines. J Clin Oncol 20 (2002) 2624-2632
20. Czerniecki B.J., Koski G.K., Koldovsky U., et al. Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion. Cancer Res 67 (2007) CAN-06-4038
21. Sengupta P.P., Northfelt D.W., Gentile F., et al. Trastuzumab-induced cardiotoxicity: heart failure at the crossroads. Mayo Clin Proc 83 (2008) 197-203
22. Korkaya H., and Wicha M.S. Her-2, Notch, and breast cancer stem cells: targeting an axis of evil. Clin Cancer Res 15 (2009) 1845-1847
23. Seidman A., Hudis C., Pierri M.K., et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 20 (2002) 1215-1221
24. Romond E.H., Prez E.A., Bryant J., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353 (2005) 1673-1684
25. Slamon D.J., Eiermann W., Robert N., et al. BCIRG 006: phase III trial comparing AC→T with AC→TH and with TCH in the adjuvant treatment of HER2-positive early breast cancer patients: second interim efficacy analysis. Breast Cancer Res Treat 100 suppl 1 (2006) (abstr)
26. Ewer M.S., Vooletich M.T., Durand J.B., et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol 23 (2005) 7820-7826
27. Peoples G.E., Gurney J.M., Hueman M.T., et al. Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients. J Clin Oncol 23 (2005) 7536-7545
28. Nagata Y., Furugen R., Hiasa A., et al. Peptides derived from a wild-type murine proto-oncogene c-erbB-2/HER2/neu can induce CTL and tumor suppression in syngeneic hosts. J Immunol 159 (1997) 1336-1343
29. + breast cancer following vaccination against Her2. J Translational Med 5 (2007) 42